NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Shares of Therapix and Immune Pharmaceuticals both saw green on Wednesday after reporting positive results from separate studies. Therapix shares moved higher after the company's drug candidate THX-ULD01 was found to significantly reverse age-related cognitive impairment in old mice. Immune skyrocketed after reporting positive results from its ongoing open-label phase 2 study of bertilimumab.
RDI Initiates Coverage on:
Therapix Biosciences Ltd.
Immune Pharmaceuticals, Inc.
Therapix Biosciences Ltd.'s shares closed up 7.29% on Wednesday with a little over 100,000 shares traded. The stock's trading volume was slightly higher than usual after the company announced preclinical results for cognitive impairment therapy. According to Professor Yosef Sarne of the Sackler Faculty of Medicine at Tel Aviv University, who conducted and designed the study, low doses of THC "could potentially provide a safe and effective treatment for cognitive decline in aging humans." Therapix's THC drug candidate THX-ULD01, a proprietary ultra-low dose THC candidate, was used in mice in the study, and results found that it significantly reversed age-related cognitive impairment in old mice. Chief Technology Officer of Therapix, Adi Zuloff-Shani, Ph.D., commented, "This promising data obtained by Professor Sarne and his team further demonstrate the clinical and commercial potential of THX-ULD01 for the treatment of MCI. Based on the discovery of significantly improved therapeutic impact at ultra-low doses (ULD) of THC, it is our continued belief that THX-ULD01 has the potential to fulfill the growing unmet medical need in MCI." Dr. Zuloff-Shani continued, "Further, this data echoes similar findings in pre-clinical models that demonstrate the neuroprotective role of ULD THC, which is expected to be followed by human trials for this potential first-in-class therapy."
Access RDI's Therapix Biosciences Ltd. Research Report at:
Immune Pharmaceuticals, Inc.'s shares closed up 16.67% on Wednesday with nearly 10 million shares traded. The big gains came after the company released early positive results from a phase 2 clinical trial. The preliminary results were from the first six subjects enrolled in the company's ongoing, open-label phase 2 study of bertilimumab in patients with moderate to severe bullous pemphigoid (BP) (study NCT02226146). It was this past February that Immune had reported results from the first three subjects. The new findings of the three new subjects confirm the previous results. Immune will continue to enroll patients in the phase 2 trial and has a target enrollment of 12 to 15 patients. The company has said it has plans for a larger clinical trial. According to the company, the first six patients in the study had "rapid" improvement, with their activity score declining on average by 72% by day 42. CEO Elliot Maza commented, "These promising preliminary results support our strategy of focusing our human capital and financial resources on our bertilimumab and NanoCyclo product candidates while streamlining our operations by divesting our unrelated oncology business. We will continue to enroll subjects into this phase 2 open-label BP trial, which has a target enrollment of 12 to 15 patients, as we initiate plans for a larger clinical trial designed to prove that bertilimumab provides a significant benefit to patients suffering from this severe inflammatory disease." Trading volume for the stock was significant yesterday compared to an average of around 650,000 shares.
Access RDI's Immune Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.